Skip to main content
OpenTrials
Completed

NCT Number: NCT05901597

Refractive Accuracy of Argos in Conjunction With the Alcon Vision Suite Following Implantation of Presbyopia Correcting IOLs

The objective is to assess refractive accuracy of the Alcon Vision Suite (with Argos biometer) following Clareon PanOptix and AcrySof Vivity IOL implantation.

Completed

Looking for future studies?

Notify Me

Key information

Age range

50 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Valley Laser Eye Centre

Abbotsford British Columbia, British Columbia, Canada

About this study

This study is a single-arm, observational study of refractive accuracy of the Alcon Vision Suite (with Argos biometer) following Clareon PanOptix and AcrySof Vivity IOL implantation. Subjects will be assessed at preoperatively, operatively, and 10 weeks post-operatively. Clinical evaluations will include measurement of monocular and binocular visual acuity, manifest refraction, and questionnaires will also be administered.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects are eligible for the study if they meet the following criteria:

Note: Ocular criteria must be met in both eyes.

  • Age-related cataract surgery (or RLE) patients that select Clareon PanOptix or AcrySof Vivity IOL.
  • Gender: Males and Females.
  • Age: 45 or older.
  • Patients motivated to increase spectacle independence with relatively low incidence of visual phenomena.
  • Willing and able to provide written informed consent for participation in the study.
  • Willing and able to comply with scheduled visits and other study procedures.
  • Have good ocular health, with no pathology that compromises visual acuity (outside of residual refractive error).

Exclusion criteria

If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study.

  • Ocular comorbidity (any previous ocular surgery, any signs of retinal disease, or glaucoma etc.) that might hamper post-operative visual acuity.
  • Irregular corneal astigmatism and keratoconus.
  • Post refractive eyes (i.e. LASIK or PRK or SMILE).
  • Patients with physical or intellectual disability (e.g. Down's Syndrome, Parkinson's Disease; unable to fixate).
  • Angle Kappa/chord mu ≥0.6.
  • Higher order corneal aberrations: > 0.6 total RMS, >0.3 coma, >0.3 trefoil (to exclude irregular corneas).

The principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates they are unsuitable for the trial.

Pregnancy has a known effect on the stability of refractions and visual acuity. As such, subjects who become pregnant during the study will not be discontinued but their data may be excluded from analyses of effectiveness.

Treatment and study plan

Clareon PanOptix and AcrySof Vivity IOL implantation Alcon Vision Suite and Argos biometer

Device

Clareon PanOptix and AcrySof Vivity IOL implantation Alcon Vision Suite and Argos biometer

Primary outcomes

  1. Monocular refractive target accuracy

    Time frame: 10 Weeks postoperative

    Percentage of subjects within predicted postoperative spherical equivalent of ± 0.5 D.

Secondary outcomes

  1. Prediction error

    Time frame: 10 Weeks postoperative

    Percentage of eyes within prediction errors (PE) of ± 0.25D, 0.75D, 1.0D

  2. Mean absolute prediction error

    Time frame: 10 Weeks postoperative

  3. Median absolute prediction error

    Time frame: 10 Weeks postoperative

  4. Uncorrected monocular visual acuity

    Time frame: 10 Weeks postoperative

    at distance (6m), intermediate (60cm), and near (40cm)

  5. Distance corrected monocular visual acuity

    Time frame: 10 Weeks postoperative

    at distance (6m), intermediate (60cm), and near (40cm)

  6. Manifest refraction

    Time frame: 10 Weeks postoperative

  7. Back-calculated Residual Astigmatism (BRA)

    Time frame: 10 Weeks postoperative

    using preoperative cylinder power (for toric IOLs)

Other outcomes

  1. Uncorrected binocular visual acuity

    Time frame: 10 Weeks postoperative

    at distance (6m), intermediate (60cm), and near (40cm)

  2. Satisfaction questionnaire

    Time frame: 10 Weeks postoperative

    The Intraocular Lens Satisfaction questionnaire (IOLSAT). Lower scores indicate higher spectacle independence and satisfaction.

  3. Visual disturbances questionnaire

    Time frame: 10 Weeks postoperative

    Questionnaire for Visual Disturbances (QUVID). Lower scores indicate less frequent, severe, or bothersome visual disturbances.

  4. Percentage of cases in which IA IOL power recommendation differed from preop calculation

    Time frame: 10 Weeks postoperative

Sponsors and collaborators

Lead sponsor

Valley Laser Eye Centre

Other

Collaborators

  • Sengi

Registry information

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Jun 13, 2023
Registry last updated
Feb 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.